Tumor necrosis factor inhibitors for rheumatoid arthritis [8]

New England Journal of Medicine

Volumn 355, Issue 19, 2006, Pages 2047-2048

  Dentener, Mieke A ^a   Wouters, Emiel F M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT;

B LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HUMAN; INFLAMMATION; LETTER; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; DRUG ANTAGONISM; NOTE; ANTIBODY PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUMOR NECROSIS FACTOR-ALPHA; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; IMMUNE TOLERANCE;

EID: 33750697229     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
2. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1414-8.
3. Rennard SI. Results of the phase II, dose finding study evaluating safety and efficacy of infliximab in patients with moderate to severe chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:A541. abstract.
4. van der Vaart H, Koeter GH, Postma DS, Kauffman HE, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-9.